Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Predicting COVID-19 incidence from seroprevalence and population-based cohort data using interpretable machine learning with differential privacy analysis

Jessica Krepel, Ruta Binkyte, Raouf Kerkouche, Manuela Harries, Carolina J. Klett-Tammen, Mario Fritz, Stefan Kesselheim, Martin Kühn, Alina Bazarova, Berit Lange, with the MuSPAD study group, RESPINOW study group
doi: https://doi.org/10.64898/2026.04.01.26349876
Jessica Krepel
1Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruta Binkyte
2CISPA – Helmholtz Center for Information Security, 66123 Saarbrücken, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raouf Kerkouche
2CISPA – Helmholtz Center for Information Security, 66123 Saarbrücken, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manuela Harries
1Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolina J. Klett-Tammen
1Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Fritz
2CISPA – Helmholtz Center for Information Security, 66123 Saarbrücken, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Kesselheim
3Jülich Supercomputing Centre, Forschungszentrum Jülich, 52425 Jülich, Germany
6Helmholtz AI, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kühn
4Institute of Software Technology, German Aerospace Center (DLR), 51147 Cologne, Germany
5Bonn Center for Mathematical Life Sciences and Institute for Life and Medical Sciences, University of Bonn, 53115 Bonn, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alina Bazarova
3Jülich Supercomputing Centre, Forschungszentrum Jülich, 52425 Jülich, Germany
6Helmholtz AI, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: al.bazarova{at}fz-juelich.de
Berit Lange
1Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
1Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
1Helmholtz Centre for Infection Research, 38124 Braunschweig, Germany
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

During the COVID-19 pandemic, reported incidence data played a central role in public health surveillance and in tracking epidemic dynamics, although they provide limited insight into the behavioral, immunological, and socioeconomic drivers of transmission.Population-based seroprevalence studies with linked survey data offer a rich but untapped source of individual-level information that can complement routine surveillance. In this study, we investigate whether aggregated seroprevalence cohort data can be leveraged to predict local COVID-19 incidence and to identify interpretable predictors associated with transmission dynamics. Using data from the Multilocal SeroPrevalence (MuSPAD) study in Germany (2020–2022), we trained multiple machine learning models, including least absolute shrinkage and selection operator (LASSO), vector autoregressive models (VAR), multilayer perceptrons (MLPs), and long short-term memory neural networks (LSTMs), to predict location-specific seven-day incidence rates. Feature importance was assessed using regression coefficients where applicable and model-agnostic explainability methods, including Local Interpretable Model-agnostic Explanations (LIME) and SHapley Additive exPlanations (SHAP). Across model classes, cohort-derived features enabled accurate prediction of local incidence, with time-aware models achieving the strongest performance. Consistent predictors included prior infection and testing history, employment-related changes, vaccination status, and mask-wearing behavior, highlighting the importance of behavioral and reporting-related signals. While differential privacy introduced modest degradation in predictive performance under strict privacy budgets, SHAP-based explanations remained stable, and LIME-based explanations were more sensitive to privacy-induced noise. These results demonstrate that aggregated cohort data encode meaningful and interpretable signals of population-level transmission dynamics. Population-based serosurveys therefore provide a complementary source of information for predicting local COVID-19 incidence and identifying key drivers of transmission beyond routine surveillance data. Our findings show that integrating interpretable machine learning with privacy-aware analysis enables actionable insights from sensitive cohort data, supporting their use in digital epidemiology and informing data-driven public health decision-making.

Author summary During the COVID-19 pandemic, public health decisions were largely based on reported case numbers. However, these data provide limited insight into the behavioral and social factors that influence how infections spread. Population-based studies that combine antibody testing with questionnaires can capture such information, but they are rarely used to predict disease dynamics at the population level. In this study, we investigated whether data from a large seroprevalence cohort study in Germany could be used to predict local COVID-19 incidence. We applied machine learning models to aggregated survey and laboratory data and used explainability methods to identify which factors were most important for the predictions. We also examined how protecting individual privacy affects both model performance and interpretation. We found that cohort-derived features can accurately predict short-term incidence trends. Key factors included prior infections, testing behavior, employment-related changes, vaccination status, and mask use. While strong privacy constraints reduced model performance, the main insights remained stable. Our results show that combining cohort data with interpretable machine learning can provide useful insights into disease dynamics. This approach may help improve future public health surveillance by incorporating information that is not captured in routine reporting systems.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by the Initiative and Networking Fund of the Helmholtz Association, Germany (grant agreement number KA1-Co-08, Project LOKI-Pandemics).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

MuSPAD complies with all relevant laws and declarations (EU Charter of Fundamental Rights, Biomedical Convention of the Council of Europe and additional protocols, the CIOMS guidelines and the Helsinki Declaration), ethical approval was given on 21.06.2020 by the Ethics Committee of the Hannover Medical School (Ethics approval no 9086_BO_S_2020). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The data underlying this study are not publicly available due to privacy and ethical restrictions related to individual-level health data. Access can be requested through the MuSPAD data access process via https://serohub.net/, subject to approval by the data custodians and applicable data protection regulations. The code used for the analyses, as well as the data codebooks and top-50 explainability tables are available at https://github.com/JesKre/Using-machine-learning-on-seroprevalence-studies-to-obtain-predictors-for-COVID-19-incidence_code

https://github.com/JesKre/Using-machine-learning-on-seroprevalence-studies-to-obtain-predictors-for-COVID-19-incidence_code

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted April 02, 2026.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Predicting COVID-19 incidence from seroprevalence and population-based cohort data using interpretable machine learning with differential privacy analysis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Predicting COVID-19 incidence from seroprevalence and population-based cohort data using interpretable machine learning with differential privacy analysis
Jessica Krepel, Ruta Binkyte, Raouf Kerkouche, Manuela Harries, Carolina J. Klett-Tammen, Mario Fritz, Stefan Kesselheim, Martin Kühn, Alina Bazarova, Berit Lange, with the MuSPAD study group, RESPINOW study group
medRxiv 2026.04.01.26349876; doi: https://doi.org/10.64898/2026.04.01.26349876
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Predicting COVID-19 incidence from seroprevalence and population-based cohort data using interpretable machine learning with differential privacy analysis
Jessica Krepel, Ruta Binkyte, Raouf Kerkouche, Manuela Harries, Carolina J. Klett-Tammen, Mario Fritz, Stefan Kesselheim, Martin Kühn, Alina Bazarova, Berit Lange, with the MuSPAD study group, RESPINOW study group
medRxiv 2026.04.01.26349876; doi: https://doi.org/10.64898/2026.04.01.26349876

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (628)
  • Allergy and Immunology (914)
  • Anesthesia (343)
  • Cardiovascular Medicine (4921)
  • Dentistry and Oral Medicine (488)
  • Dermatology (421)
  • Emergency Medicine (667)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1654)
  • Epidemiology (16112)
  • Forensic Medicine (35)
  • Gastroenterology (1225)
  • Genetic and Genomic Medicine (7161)
  • Geriatric Medicine (740)
  • Health Economics (1079)
  • Health Informatics (5179)
  • Health Policy (1452)
  • Health Systems and Quality Improvement (1805)
  • Hematology (594)
  • HIV/AIDS (1361)
  • Infectious Diseases (except HIV/AIDS) (16392)
  • Intensive Care and Critical Care Medicine (1187)
  • Medical Education (684)
  • Medical Ethics (156)
  • Nephrology (733)
  • Neurology (7431)
  • Nursing (372)
  • Nutrition (1108)
  • Obstetrics and Gynecology (1272)
  • Occupational and Environmental Health (1018)
  • Oncology (3682)
  • Ophthalmology (1076)
  • Orthopedics (400)
  • Otolaryngology (460)
  • Pain Medicine (487)
  • Palliative Medicine (142)
  • Pathology (714)
  • Pediatrics (1834)
  • Pharmacology and Therapeutics (742)
  • Primary Care Research (780)
  • Psychiatry and Clinical Psychology (6026)
  • Public and Global Health (9877)
  • Radiology and Imaging (2477)
  • Rehabilitation Medicine and Physical Therapy (1492)
  • Respiratory Medicine (1257)
  • Rheumatology (653)
  • Sexual and Reproductive Health (791)
  • Sports Medicine (590)
  • Surgery (790)
  • Toxicology (109)
  • Transplantation (313)
  • Urology (299)